# Comparing Retatrutide and Mounjaro for Weight Loss Injections > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/retatrutide-weight-loss-injections-vs-mounjaro/ > **Published:** 2026-05-11T16:45:34-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T17:00:59-04:00 > **Clinical Summary:** Explore retatrutide weight loss injections and their advantages over Mounjaro in GLP-1 receptor agonist therapy for obesity and metabolic disease. --- GLP-1 Clinical Relevance  #55Moderate Clinical Relevance  Relevant context for GLP-1 prescribers; interpret with care. ⚕ GLP-1 News  |  CED Clinic Clinical CommentaryComparative AnalysisObesity ManagementTirzepatideType 2 DiabetesEndocrinologyAdults with ObesityWeight Loss OutcomesDual GLP-1 and GIP Receptor AgonismRetatrutide Triple AgonistUK Prescription MedicationsMetabolic Disease Treatment Why This Matters Retatrutide represents a novel triple GIP/GLP-1/glucagon receptor agonist that demonstrates superior weight loss efficacy compared to tirzepatide (Mounjaro) in phase 3 trials, with mean reductions exceeding 22% of baseline body weight versus approximately 20% for tirzepatide. For family physicians, understanding this pharmacologic distinction is clinically relevant because retatrutide’s additional glucagon receptor pathway may offer differential metabolic benefits and potential advantages in specific patient phenotypes, though tirzepatide remains the only currently FDA-approved agent in this class for chronic [weight management](https://cedclinic.com/cannabis-metabolism-weight-management-science/). The comparative efficacy and tolerability profiles should inform individualized treatment selection once retatrutide achieves regulatory approval and becomes available in clinical practice. Clinical Takeaway Retatrutide and tirzepatide are both GLP-1 receptor agonists available in the UK for [weight management](https://cedclinic.com/cannabis-metabolism-weight-management-science/) and glycemic control, with retatrutide showing additional benefits through triple-hormone receptor agonism. Both medications require prescription-level oversight and carry similar contraindications including personal or family history of medullary thyroid carcinoma. Clinical efficacy differs between agents, with retatrutide demonstrating greater weight loss in comparative trials, though tirzepatide remains the current standard of care with longer real-world safety data. When counseling patients, frame medication selection around individual metabolic profiles, contraindications, and whether additional metabolic benefit justifies potential differences in tolerability or cost. Dr. Caplan’s Take “While tirzepatide has become a cornerstone agent in my practice for metabolic disease management, the emergence of retatrutide represents a meaningful evolution in the GLP-1/GIP/glucagon receptor agonist class, with early data suggesting superior weight loss efficacy in certain patient populations. Both agents require careful patient selection and metabolic assessment, but the key clinical distinction lies in their mechanistic targeting, which influences both efficacy and side effect profiles. From a patient communication standpoint, I find it essential to frame these newer agents not as weight-loss injections but rather as metabolic regulators that happen to produce weight loss as a beneficial secondary outcome, which fundamentally changes how patients understand their role in treatment. The reality in 2024 is that we have multiple tools in our armamentarium, and the evidence will continue to evolve as real-world data accumulates.” Clinical Perspective Retatrutide represents the next-generation triple agonist (GLP-1/GIP/glucagon receptor) that demonstrates superior weight loss compared to tirzepatide across [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/), positioning it as a potential successor in the incretin-based therapy hierarchy once regulatory approval and access expand beyond investigational settings. The clinical distinction hinges on retatrutide’s additional glucagon receptor engagement, which enhances metabolic rate and hepatic glucose production suppression, making it particularly relevant for patients who plateau on tirzepatide or require more aggressive glycemic control alongside weight reduction. Clinicians should prospectively document baseline metabolic parameters, gastrointestinal tolerance patterns, and weight loss trajectory in current tirzepatide patients to facilitate evidence-based transition decisions when retatrutide becomes available, while remaining alert to potential pancreatitis risk given the enhanced metabolic potency of triple receptor activation. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Retatrutide%20vs%20Mounjaro%20%7C%20Best%20%3Cb%3Eweight-loss%20injections%3C%2Fb%3E%20in%20the%20UK%20-%20Second%20%20%40drcaplan&url=https%3A%2F%2Fwww.secondnature.io%2Fguides%2Fweight-loss-medications%2Fretatrutide-vs-mounjaro)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.secondnature.io%2Fguides%2Fweight-loss-medications%2Fretatrutide-vs-mounjaro)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Retatrutide%20vs%20Mounjaro%20%7C%20Best%20%3Cb%3Eweight-loss%20injections%3C%2Fb%3E%20in%20the%20UK%20-%20Second%20%20--%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fwww.secondnature.io%2Fguides%2Fweight-loss-medications%2Fretatrutide-vs-mounjaro)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [Read full article at Secondnature](https://www.secondnature.io/guides/weight-loss-medications/retatrutide-vs-mounjaro) Nationwide GLP-1 Care Looking for thoughtful, physician-led GLP-1 guidance? CED Clinic offers GLP-1 and metabolic guidance across the United States, including evaluation, prescribing support, side-effect management, and longer-term follow-up for people seeking careful, personalized care. [Learn More](https://cedclinic.com/metabolic/) [Book Now](https://book.squareup.com/appointments/kn3vehwoiz6to6/location/DPV0VF8Y74WA7/services) Table of Contents - [FAQ](#FAQ)[What is the difference between Mounjaro and retatrutide?](#What_is_the_difference_between_Mounjaro_and_retatrutide) - [Is Mounjaro approved for weight loss in the UK?](#Is_Mounjaro_approved_for_weight_loss_in_the_UK) - [How do GLP-1 medications like these actually help you lose weight?](#How_do_GLP-1_medications_like_these_actually_help_you_lose_weight) - [Will I need to stay on Mounjaro forever to keep the weight off?](#Will_I_need_to_stay_on_Mounjaro_forever_to_keep_the_weight_off) - [Are there serious side effects I should know about with GLP-1 injections?](#Are_there_serious_side_effects_I_should_know_about_with_GLP-1_injections) - [How quickly will I see weight loss results with these medications?](#How_quickly_will_I_see_weight_loss_results_with_these_medications) - [Can I use Mounjaro or retatrutide if I have diabetes?](#Can_I_use_Mounjaro_or_retatrutide_if_I_have_diabetes) - [What is the cost of GLP-1 weight loss injections in the UK?](#What_is_the_cost_of_GLP-1_weight_loss_injections_in_the_UK) - [How often do I need to inject Mounjaro or retatrutide?](#How_often_do_I_need_to_inject_Mounjaro_or_retatrutide) - [What should I do if I want to try GLP-1 therapy but I am worried about side effects?](#What_should_I_do_if_I_want_to_try_GLP-1_therapy_but_I_am_worried_about_side_effects) - [Related](#Related) ## FAQ #### What is the difference between Mounjaro and retatrutide? Mounjaro (tirzepatide) is an FDA-approved medication that works on two hormone pathways to help with weight loss and blood sugar control. Retatrutide is a newer medication still in development that targets three hormone pathways, potentially offering additional benefits for weight management. #### Is Mounjaro approved for weight loss in the UK? Yes, Mounjaro is approved as a prescription medication in the UK for managing obesity and type 2 diabetes. Your doctor can prescribe it if they determine it is appropriate for your individual health needs. #### How do GLP-1 medications like these actually help you lose weight? These medications work by reducing your appetite, helping you feel fuller longer, and improving how your body regulates blood sugar. This combination makes it easier to eat less and maintain weight loss over time. #### Will I need to stay on Mounjaro forever to keep the weight off? Most patients benefit from staying on the medication long-term because weight typically returns when treatment stops. Your doctor can discuss the right duration based on your individual health goals and response to treatment. #### Are there serious side effects I should know about with GLP-1 injections? Common [side effects](https://cedclinic.com/cannabis-intoxication-memory-disruption/) include nausea, vomiting, and constipation, which often improve over time. Rare but serious risks exist, so you must discuss your full medical history with your doctor before starting. #### How quickly will I see weight loss results with these medications? Most people begin noticing weight loss within the first few weeks, with more significant results typically appearing over three to six months. Individual responses vary based on factors like diet, exercise, and overall health. #### Can I use Mounjaro or retatrutide if I have diabetes? Yes, both medications can treat type 2 diabetes and are often prescribed specifically for this purpose. They help control blood sugar while also promoting weight loss, offering dual benefits for many patients. #### What is the cost of GLP-1 weight loss injections in the UK? Costs vary depending on whether treatment is through the NHS or private practice, and specific pricing should be discussed with your healthcare provider or clinic. Insurance coverage and eligibility criteria also affect what you will pay out of pocket. #### How often do I need to inject Mounjaro or retatrutide? Both medications are typically given as weekly injections that you can administer yourself at home. Your doctor will provide specific instructions on timing and injection technique during your initial consultation. #### What should I do if I want to try GLP-1 therapy but I am worried about side effects? Start by having an honest conversation with your doctor about your concerns so they can address them and monitor you closely. Starting at the lowest dose and making gradual increases allows your body to adjust while minimizing [side effects](https://cedclinic.com/cannabis-intoxication-memory-disruption/). [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Tirzepatide vs Retatrutide: Efficacy Safety Comparison](https://cedclinic.com/retatrutide-weight-loss-efficacy-vs-tirzepatide/) A detailed clinical comparison of tirzepatide and retatrutide focusing on efficacy and safety profiles for weight management. [Read More](https://cedclinic.com/retatrutide-weight-loss-efficacy-vs-tirzepatide/) [Retatrutide vs Semaglutide: Clinical Evidence & Efficacy](https://cedclinic.com/retatrutide-clinical-evidence-efficacy-weight-loss/) Explore clinical evidence comparing retatrutide and semaglutide for weight loss and metabolic disease treatment. [Learn More](https://cedclinic.com/retatrutide-clinical-evidence-efficacy-weight-loss/) [GLP-1 Weight Loss: Clinical Evidence and Outcomes](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/) Comprehensive review of GLP-1 receptor agonists and their outcomes in weight loss and [metabolic health](https://cedclinic.com/cannabis-compounds-reverse-fatty-liver-disease/). [Discover Insights](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).